Nextrans
VC Fund
Seoul, South Korea
Nextrans is an early-stage Venture Capital firm, which invests in tech-enabled startups in 3 markets: Vietnam, Korea and the US. We invest in diverse sectors: E-commerce, Fintech, Edtech, Healthcare, EV,... Up to now, we have proudly backed and supported more than 100 companies in total 3 markets.Our mission is to create a global network oftalented and passionate founders pursuing world-changing impact. We want to transform the lives of human race by leveraging state-of-the-art technology and empowering disruptive startups on timeless philosophy “Trust, Sharing and Passion”In the years ahead, we will maintain our primary focus on Korean and Vietnamese markets. We have a burning desire to build our portfolio into a robust startup ecosystem and cultivate the next generation of mighty founders.
- Total investments:
- 62
- Last investment:
- Lead investor:
- 8%
- Fund size:
- $50M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Nextrans invests in
Stages Nextrans invests in
Countries Nextrans invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $865k–$4.5M
- Series A
- $1.9M–$14M
- Series B
- $9M–$15M
Investment Focus
Industry
- Information Technology 9 (15%)
- Software 8 (13%)
- E-Commerce 8 (13%)
- Health Care 7 (11%)
- EdTech 5 (8%)
Stage
- Seed 33 (53%)
- Series A 12 (19%)
- Series B 3 (5%)
- Funding Round 3 (5%)
- Series D 2 (3%)
Country
- Vietnam 24 (39%)
- South Korea 16 (26%)
- United States 9 (15%)
- Singapore 2 (3%)
- Australia 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Chris Chae
Managinng Director
|
Managinng Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Kalivir designs safe and potent oncolytic product candidates across multiple tumor types. Kalivir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh’s world-class oncolytic virus and immunotherapy research programs. | $14M / Series A / Aug 19, 2026 | ||
| Qum Therapeutics Develops immunotherapies that target pathogenic cells. The company designs treatments to engage the patient’s immune system and control disease progression. Its approach focuses on precision targeting and minimizing side effects. The technology is applied to cancer and other diseases that involve pathogenic cells. | $10M / Seed / Nov 30, 2025 | ||
| In the new digital transformation era, connecting every touchpoint for every stakeholder on the journey is crucial in helping businesses create a competitive advantage. Filum enables businesses to build a foundation that promotes creativity and the power of inner strengths to make journeys of excellence. We empower businesses by helping them createexcellent experiences with the power of data and cutting-edge technologies. | $1M / Seed / Mar 17, 2025 | ||
| Applying to university is stressful. Students dont know how! None knows what they want to major in at university when they are just 16 years old! Parents cant help. Teachers cant help. And education consultants are too expensive for most families. We are Major Map and our data driven AI technology platform helps teachers and parents guide highschool students to the right major based on their personality and interests. Since we launched Major Map three years ago over twenty percent of the high school students in South Korea have used our service. The massive amount of data from our user base gives our AI models a huge advantage. Lets connect and I can introduce how we are revolutionizing education counseling with technology. | Series A / Dec 12, 2024 | ||
| Mediintech develops smart endoscopes for the digestive system. | $14.7M / Series B / May 13, 2024 | ||
| Bungee is a recruitment platform. It connects verified talent in a project format. It provides a service that matches corporate clients with employees who have already achieved results in similar environments to solve problems faced by corporate clients in various fields such as marketing, global expansion, and development. | $1.5M / Seed / Mar 26, 2024 | ||
| ScaleUP offers innovative solutions to omnichannel merchants who want to develop their business and revenue easily and efficiently. | Seed / Mar 21, 2024 | ||
| Colosseum is a logistics company that provides e-commerce logistics services to various locations. | Series A / Oct 30, 2023 | ||
| AIVIS is a specialized computational pathology company that provides AI-driven solutions for the quantification of IHC biomarkers, directly addressing the "Precision Gap" in oncology and drug development. As a clinical-stage AI company, AIVIS transforms subjective slide interpretation into objective, traceable data to support bothclinical decision-making and pharmaceutical R&D. [Clinical Leadership & Market Presence] Originally established as the first official spin-off from Samsung Medical Center (SMC), AIVIS has rapidly transitioned from research to routine clinical practice. -Market Adoption: Within one year of regulatory approval, AIVIS's solutions have been deployed in over 20 leading hospitals in South Korea, capturing approximately 25% of the domestic market. -Proven Utility: In large-scale clinical studies involving 38 pathologists across 20 institutions, AIVIS demonstrated a significant reduction in inter-observer variability, drastically improving diagnostic consistency in complex cases. [Strategic Partnerships with Global Leaders] AIVIS is at the forefront of building a global digital pathology ecosystem through high-level strategic collaborations: -AstraZeneca: Signed an MOU to develop an AI-powered HER2 diagnostic ecosystem, optimizing patient screening for next-generation therapies like Antibody-Drug Conjugates (ADCs). -Philips Korea: Secured a License Agreement to integrate AIVIS’s quantification engines (Qanti® IHC) into Philips’ global pathology solutions, enhancing diagnostic workflows for various cancer biomarkers. [Comprehensive Product Portfolio] -Qanti® IHC: An MFDS-approved clinical decision support software designed for high-accuracy patient screening in routine clinical environments. It ensures auditable and regulatory-compliant data for formal diagnosis. -Qanti® Discovery: A translational research tool that automates cell quantification for drug development. It streamlines reporting for regulatory submissions and accelerates decision-making in clinical trials by providing standardized scoring. [Vision for Precision Medicine] AIVIS is continuously expanding its capabilities beyond breast and gastric cancers to include lung, prostate, and colon cancers. By co-developing specialized tools with global pharmaceutical partners, AIVIS is bridging the gap between early-stage biomarker discovery and scalable, worldwide clinical application, ensuring that every patient receives the most accurate diagnosis for personalized treatment. | $4M / Seed / Sep 16, 2023 | ||
| Bbodek provider of tableware rental and washing services intended for restaurants and school cafeterias. They provide products for children's tableware and hygiene management services. They specialize in using their self-developed smart factory to render low defect services to consumers, enabling them to just focus on cooking without worryingabout cleaning up. They are expanding their business to customized washing machine manufacture and sales. | $13.5M / Series B / Sep 07, 2023 | ||
| See all 62 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Nextrans invest in?
Nextrans invests primarily in Information Technology, Software and E-Commerce startups, most often at Seed and Series A stage. Most of the 62 investments tracked by Shizune back companies in Vietnam. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Nextrans's check size?
Nextrans typically joins rounds of $865k–$4.5M at Seed, $1.9M–$14M at Series A and $9M–$15M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Nextrans participates in.
How do I contact Nextrans?
Public channels for Nextrans include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Nextrans?
The team at Nextrans includes Chris Chae (Managinng Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
